Ki67 antibody human specific - 398 003 (HS-398 003)

Ki67 is a marker protein for proliferating cells

 

Attention: Due to the merger of the SYSY-Antibodies and HistoSure websites, our catalog numbers are being harmonized. The HS prefix will be removed, and only the SYSY-Antibodies format will remain. The product itself is unchanged.

Rabbit polyclonal purified antibody
Cat. No.: 398 003
Amount: 200 µl
Price: $455.00
Cat. No. 398 003 200 µl specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not tested yet
IP: not tested yet
ICC: not tested yet
IHC: not tested yet
IHC-P (FFPE): 1 : 100 gallery

Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section.

Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section.

Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.

Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.

Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.

Immunogen Synthetic peptide corresponding to AA 1251 to 1271 from human Ki67 (UniProt Id: P46013)
Reactivity Reacts with: human (P46013).
No signal: mouse (E9PVX6), pig.
Other species not tested yet.
Data sheet Data Sheet 398_003

References for Ki67 - 398 003

Integrin-targeting cyclic peptides suppress TGF-β1-driven EMT and invasion in third-generation EGFR-TKI-resistant NSCLC.
Seo J, Kim J
Chemico-biological interactions (2026) 434: 112117. 398 003 IHC; tested species: human
Cat. No.: 398 003
Amount: 200 µl
Price: $455.00

Detection of proliferation antigen Ki-67 in cells of human (red) and murine (brown) origin in various xenograft models

Integrin-targeting cyclic peptides suppress TGF-β1-driven EMT and invasion in third-generation EGFR-TKI-resistant NSCLC.
Seo J, Kim J
Chemico-biological interactions (2026) 434: 112117. 398 003 IHC; tested species: human
Background

Ki-67 is a nuclear protein which is widely used as a marker of cell proliferation. Its expression is closely associated with the cell cycle: Ki-67 is present in actively cycling cells during the G1, S, G2, and M phases but is generally absent in quiescent cells in the G0 phase. At the cellular level, Ki-67 is predominantly localized in the nucleus during interphase and redistributes to the periphery of condensed chromosomes during mitosis (1,2).
Immunohistochemical staining for Ki-67 is a simple and reproducible method to determine the tumor proliferative index and is a predictive and prognostic biomarker in certain types of human cancer, such as breast cancer, gastric cancer or prostate cancer. In breast cancer higher Ki-67 levels have been associated with an increased risk of disease recurrence (1,3). However, Ki-67 expression is not specific to malignant cells, as it is also present in normally proliferating tissues and activated lymphocytes.

Certificates

ISO 9001 2015 Quality Management System and Green Lab Platinum certification level for sustaining laboratory processes.

Newsletter

Sign up for our newsletter and get the latest updates and news.
 

Please provide a valid E-Mail-Address
Please provide a valid First name
Please provide a valid Last name